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ttp://dx.doi.org/10.1016/j.ajpath.2013.08.030With this study we have demonstrated that in vitro transduction of normal human CD4þ T lymphocytes with
NPM-ALK results in their malignant transformation. The transformed cells become immortalized and display
morphology and immunophenotype characteristic of patient-derived anaplastic large-cell lymphomas.
These unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual
cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and
mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosup-
pressive cytokine IL-10 and cell-surface protein PD-L1/CD274. Implantation of NPM-ALKetransformed
CD4þ T lymphocytes into immunodeﬁcient mice resulted in formation of tumors indistinguishable from
patients’ anaplastic large-cell lymphomas. Our ﬁndings demonstrate that the key aspects of human carci-
nogenesis closely recapitulating the features of the native tumors can be faithfully reproduced in vitro when
an appropriate oncogene is used to transform its natural target cells; this in turn points to the fundamental
role in malignant cell transformation of potent oncogenes expressed in the relevant target cells. Such
transformed cells should permit study of the early stages of carcinogenesis, and in particular the initial
oncogeneehost cell interactions. This experimental design could also be useful for studies of the effects of
early therapeutic intervention and likely also the mechanisms of malignant progression. (Am J Pathol 2013,
183: 1971e1980; http://dx.doi.org/10.1016/j.ajpath.2013.08.030)Supported in part by NIH grants R01-CA89194 (M.A.W.), R01-
CA96856 (M.A.W.), P01-AI080192 (J.L.R.), and R01-CA147795 (J.L.R.).
Q.Z. and F.W. contributed equally to this work.Anaplastic large-cell lymphomas (ALCLs) carrying anaplastic
lymphomakinase (ALK)comprise adistinct clinicopathological
entity.1e3 ALKþ ALCLs are derived from CD4þ T lympho-
cytes, typically occur in children and young adults, and involve
soft tissues and other extranodal sites. As the name implies,
ALCLs consist of large, highly atypical cells with prominent
nuclei and abundant cytoplasm and thus bear little resemblance
to their normal CD4þ T-cell counterparts, either resting or
activated. They also display a unique phenotype, with variable
loss of CD3 and other T-cell markers and strong expression of
CD30 (a cell surface receptor in the TNF-R superfamily).
Although ALK is physiologically expressed only in a subset
of immature neuronal cells,1 its aberrant expression has been
identiﬁed in a subset of ALCL4,5 and subsequently also in a
spectrum of histologically diverse malignancies, including
subsets of a large B-cell lymphoma, inﬂammatory myoﬁbro-
blastic tumor, and nonesmall cell lung carcinoma.1e3 The
aberrant expression of ALK typically results in these malig-
nancies from chromosomal translocations involving the ALKstigative Pathology.
.gene and various partner genes, with the nucleophosmin gene
(NPM1; alias NPM ) being by far the most common partner in
ALKþ ALCL.1 The NPM-ALK chimeric protein is constitu-
tively activated through autophosphorylation4,5 and is highly
oncogenic, as has been documented mainly in patient-derived
cell lines and transgenic mouse models.6e10 NPM-ALK acti-
vates a number of signal transduction pathways, including
STAT311,12 and mTORC1 (along with its downstream target,
S6RP).13 Chronic activity of these signaling pathways leads to
the persistent modulation of a number of genes, which results in
sustained cell proliferation, resistance to cell death, and other
oncogenicproperties.NPM-ALKis capableof fostering evasion
of the antitumor immune response by inducing expression of
potent immunosuppressiveproteins (namely, the cytokine IL-10
and the cell membrane bound ligand PD-L1/CD274).14,15
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Lentiviral Transduction of CD4þ T Lymphocytes
Deidentiﬁed puriﬁed human CD4þ T cells were obtained
from the Human Immunology Core facility at the University
of Pennsylvania under an Institutional Review Boarde
approved protocol. The CD4þ T cells were activated by
coculture with anti-CD3/28 antibody-coated beads at a 1:3
cell/bead ratio. The cells were transduced 24 hours later by
exposure to lentiviral vectors containing NPM-ALK (wild
type or kinase-deﬁcient K210R mutant) either alone or
together with GFP as part of T2A fusion construct. Fresh
medium was added to the cells on day 3 and twice weekly
thereafter. On day 5, the magnetic beads were removed.
Transduction efﬁciency was determined using ﬂow cytom-
etry to examine expression of GFP or NPM-ALK; the latter
was accomplished using anti-ALK antibody (J606; BD
Biosciences, San Jose, CA) and a Cytoﬁx/Cytoperm ﬁxation
and permeabilization kit (BD Biosciences).
Cell Lines
The standard cell lines used in the present study have been
described previously.13e15 In brief, the SUDHL-1 [obtained
from Dr. Stephen Morris (St. Jude Hospital, Memphis, TN)]
and JB6 cell lines were derived from ALKþ ALCL and the
2A (Mac-2A) cell line was derived from the primary cuta-
neous ALK-ALCL [both obtained from Dr. Marshall Kadin
(Beth Israel Hospital, Boston MA)]. The MyLa2059 and
MyLa3675 cell lines were derived from cutaneous T-cell
lymphomas and obtained fromDr. Niels Ødum (University of
Copenhagen, Copenhagen, Denmark). The Jeko cell line was
derived from a mantle B-cell lymphoma and obtained from
Dr. Raymond Lai (University of Alberta, Edmonton, AB,
Canada). HEK 293 cells are derived from human embryonic
kidney and purchased from the ATCC (Manassas, VA).
Western Blotting
Western blotting was performed using antibodies against
p-ALK, p-STAT3, p-S6RP, total S6RP (all from Cell
Signaling Technology, Danvers, MA), total NPM-ALK (BD
Pharmingen, San Diego, CA), and total STAT3 and b-actin
(both from Santa Cruz Biotechnology, Santa Cruz, CA),
according to standard protocols.
Cell Migration
Cells were incubated for 20 hours in fetal bovine serumefree
RPMI1640 medium, washed, resuspended in quenching me-
dium (5% bovine serum albumineRPMI). They were applied
at concentration of 2 106/mL in 250mL to the top chamber of
the Transwell culture system (MilliporeeChemicon Interna-
tional, Temecula, CA) and 400 mL of RPMI medium with
fetal bovine serumwas added to the lower chamber. The plates
were covered and incubated for 24 hours at 37C in a 5%1972CO2eenriched atmosphere. Cells that passed through the
membrane were collected from the lower chamber and added
to a 96-well plate. Lysis buffer and dye solution containing
CyQUANT green dye (Life Technologies) was added to
all samples for 15 minutes at room temperature, and the plate
was examined with a ﬂuorescence plate reader (Molecular
Devices, Sunnyvale, CA) using a 480/520-nm ﬁlter set.
Colony Formation
Cells were plated for 21 days in semisolid agar prepared
according to the standard protocol. The number of growing
colonies was counted using an inverted light microscope.
Flow Cytometry
The cells were analyzed using a FACSCalibur ﬂuorescence-
activated cell sorting system (BD Biosciences), and the data
acquisition and analysis were performed using CellQuest Pro
software version 6.03 (BDBiosciences). For the standard cell-
surface staining, 0.5  106 to 1.0  106 cells were incubated
for 20 minutes at 4C with 10 to 20 mL of ﬂuorescein
isothiocyanateeconjugated, phycoerythrin-conjugated, or
allophycocyanin-conjugated standard antieT-cell and antie
B-cell antibodies, PD-L1, or isotype control antibody (Bio-
Legend, San Diego, CA). The intracellular staining was per-
formed by using commercially available ﬁxation and
permeabilization reagents from BD Biosciences or from Life
Technologies (Carlsbad, CA). In brief, 0.5 106 to 1.0 106
washed membrane-stained or unstained cells were ﬁxed for
15 minutes at room temperature with 100 mL of ﬁxation
and permeabilization solution or ﬁxation medium. After
washing the cells were resuspended in 100 mL of PBS or
permeabilization medium, and incubated for 15 minutes at
room temperature with 10 to 20 mL of phycoerythrin-labeled
ALK or isotype control antibody (BD Biosciences). After
additional washing, cells were analyzed by ﬂow cytometry
using a FACSCalibur system (BD Biosciences); data acqui-
sition and analysis were performed using CellQuest Pro
software version 6.03 (BD Biosciences).
Immunohistochemistry
Immunohistochemical staining was performed on formalin-
ﬁxed, parafﬁn-embedded cell blocks or xenotransplant
tumor tissues using standard methods. In brief, the slides
were heat-treated for antigen retrieval in 10 mmol/L citrate
buffer and sections were incubated with diluted primary
antibodies to ALK, CD30, CD2, MUM1, Ki-67 (all from
Dako, Carpinteria, CA), and CD3 (Novocastra; Leica
Microsystems, Wetzlar, Germany). For interpretation, the
immunostained slides were evaluated by light microscopy.
Cytogenetics
A metaphase-arresting colcemid solution was added to cell
cultures for 2 hours. Cells were exposed to hypotonicajp.amjpathol.org - The American Journal of Pathology
NPM-ALK Transforms Normal Human T Cellssolution for 40 minutes at 37C, followed by three changes
of 1:3 glacial acetic acid/methanol solution. The cell sus-
pension was dropped onto water-wetted microscope slides.
Dried slides were aged in an oven at 600C for 14 hours and
stained with Wright’s stain for G-banding. Metaphase
spreads were analyzed under a bright-ﬁeld microscope
at 100 magniﬁcation, images were captured, and karyo-
types were prepared using GeneVision (Applied Imaging,
Santa Clara, CA).
T-Cell Receptor Gene Rearrangement
DNA was extracted from cultured cells using conventional
column-based methods (Qiagen, Valencia, CA). Two
separate multiplex PCR ampliﬁcations were performed,
using primers to relatively well-conserved regions in the
V and J gene segments of the T-cell receptor gamma locus
(TRG). PCR products were separated by capillary electro-
phoresis using an ABI 3130xl system (Life Technologies).
Peak size and height were determined using GeneMapper
software version 3.7 (Life Technologies). PCR product sizes
are expected to range between 200 bp and 250 bp for the
TRG V gene segments 1 to 8 primer mix, and between 150
bp and 200 bp for the TRG V gene segments 9 to 11 primer
mix.
siRNA Assay
A mixture of four siRNAs speciﬁc for ALK or control
siRNAs (Dharmacon; Thermo Fisher Scientiﬁc, Waltham,
MA) was introduced into cells for 72 hours using Lip-
ofectamine 2000 transfection reagent (Life Technologies) as
described previously15 for SUDHL-1 cells and Nucleofector
Solution T (Amaxa; Lonza, Walkersville, MD) for CD4þ
T-cellederived NA1 cells.
IL-10 Assay
IL-10 expression was examined using a human cytokine
10-plex antibody bead kit (Life Technologies) according to
the manufacturer’s protocol. Sample acquisition was per-
formed using a Luminex FlexMAP-3D system (Life
Technologies), and analyses were performed using the
associated xPONENT software version 4.0. A nine-point
standard curve at threefold dilutions was used, with the
range deﬁned by 80% to 120% of expected/observed
values. Samples were tested in duplicate, and the coefﬁ-
cient of variation was <10%. Results are expressed as
decrease in cells treated with the ALK inhibitor CEP-
28122, relative to untreated cells.
RT-qPCR
For reverse transcription quantitative PCR (RT-qPCR), total
RNA was extracted using a Qiagen RNeasy kit and was
reverse-transcribed using anABI high-capacity RNA-to-cDNAThe American Journal of Pathology - ajp.amjpathol.orgkit (Life Technologies). Expression levels of NPM-ALK
mRNA were quantiﬁed by using an ABI PRISM 7700
sequence detection system with TaqMan gene expression
assay kits (NPM-ALK, Hs03024829; b-actin, Hs9999903)
(Life Technologies) and SYBR Green assay (Life Technol-
ogies), using forward and reverse primers for IL-10 (50-
AAGGCGCATGTGAACTCC-30 and 50-AAGGCATTCTT-
CACCTGCTC-30) and for GAPDH (50-TCTCCAGAACA-
TCATCCCTGCCTC-30 and 50-TGGGCCATGAGGTCCA-
CCACCCTG-30). All assays were performed in duplicate.
The fold difference in RNA levels was calculated on the basis
of the difference between CT values (DCT) obtained for
control and individual mRNA.MTT Enzymatic Conversion Assay
Cells suspended at 2  104 cells per well were incubated at
37C in microtiter plates for up to 44 hours, then incubated
with MTT (Promega, Madison, WI) for 4 hours. Well
contents were solubilized overnight in the medium con-
taining 10% SDS and 0.01 mol/L HCl. Absorbance at 570
nm in each well was measured using a Titertek Multiskan
spectrophotometer (Thermo Fisher Scientiﬁc).Bromodeoxyuridine Incorporation Assay
The assay was performed using a cell-proliferation enzyme-
linked immunosorbent assay (ELISA; Roche Diagnostics,
Indianapolis, IN) according to the manufacturer’s protocol.
In brief, cells were cultured at a concentration of 2  104
cells per well for 44 hours and labeled with bromodeox-
yuridine for 4 hours. After centrifugation, supernatant
removal, and plate drying, the cells were ﬁxed and the DNA
was denatured using FixDenat reagent (Roche Diagnostics).
The amount of incorporated bromodeoxyuridine was
determined by incubation with a speciﬁc antibody conju-
gated with horseradish peroxidase, followed by colorimetric
conversion of the substrate and absorbance evaluation in the
ELISA plate reader.TUNEL Assay for DNA Fragmentation
TUNEL assay was performed using an ApoAlert DNA
fragmentation assay kit (BD Biosciences) according to the
manufacturer’s protocol. In brief, cells were cultured at
0.5  104 cells per well for 48 hours and then were
collected, washed, ﬁxed, permeabilized with 70% ethanol,
washed again, and incubated in terminal deoxynucleotidyl
transferase incubation buffer for 1 hour at 37C. The reac-
tion was stopped by adding 20 mmol/L EDTA. The cells
were washed twice, resuspended in 0.5 mL of propidium
iodideeRNaseePBS, collected, and analyzed by ﬂow
cytometry using a FACSCalibur system (BD Biosciences);
data acquisition and analysis were performed using Cell-
Quest Pro software (BD Biosciences).1973
Zhang et alAnnexin V Expression Assay
For annexin V expression assay, cells were treated with the
ALK inhibitor CEP-28122 (100 nmol/L) for 48 hours or
with ALK siRNA (100 pmol/L) for 72 hours. After treat-
ment, cells were washed with PBS and stained with antie
annexin V antibody and propidium iodide for 10 minutes,
according to the manufacturer’s instructions (Roche Di-
agnostics). The stained cells were analyzed by ﬂow
cytometry using a FACSCalibur system (BD Biosciences);
data acquisition and analysis were performed using Cell-
Quest Pro software (BD Biosciences).
Mouse Xenograft Tumor Formation
For tumor growth studies, NOD/SCID/IL-2Rgcnull (NSG;
stock no. 005557; Jackson Laboratory, Bar Harbor, ME)
mice were generated at the Stem Cell and Xenograft Core
facility (University of Pennsylvania School of Medicine)
using stock breeders obtained from the Jackson Laboratory.
Mice were housed in sterile conditions using HEPA-ﬁltered
microisolator cages and were fed with irradiated food and
acidiﬁed water. All experiments were performed using mice
aged 8 weeks. The protocol was approved by the Institu-
tional Animal Care and Use Committee. The NPM-
ALKetransformed CD4þ T-cell lines NA1 and ALKþ
ALCLederived SUDHL-1 line were transduced to express
luciferase. On day 0, individual mice were implanted with
3  106 cells by intraperitoneal administration. Mice were
monitored weekly for tumor growth by visual examination
and, starting with week 3, by bioluminescence imaging,
which was performed on anesthetized mice using a Xenogen
Spectrum system and Living Image software version 3.2
(CaliperePerkinElmer, Hopkinton, MA). For imaging, 10
mg/kg D-luciferin (CaliperePerkinElmer) suspended in PBS
at a concentration of 15 mg/mL was administered intra-
peritoneally. Mice were imaged at 12 minutes after luciferin
injection, and serial images were collected at various ex-
posures. Data were analyzed with Living Image software
version 3.2, using images taken with identical settings for
mice in each group at each time point. Imaging data were
converted to photons/second, photons/cm2, and photons/
steradian to normalize each image for exposure time, f-stop,
binning, and mouse size.
Results
NPM-ALK Induces Malignant Transformation of Normal
CD4þ T Lymphocytes
Given the highly oncogenic phenotype of NPM-ALK and
the CD4þ T-cell derivation of ALKþ ALCL,1e3 we trans-
duced puriﬁed normal CD4þ T lymphocytes with lentiviral
vector expressing the kinase, after having preactivated the
cells with anti-CD3 and anti-CD28 antibodies to foster an
effective transduction. Separate pools of the preactivated1974CD4þ T cells were transduced with either an NPM-ALK
mutant devoid of enzymatic activity (NPM-ALK-KD) or
were left untransduced. Transfection with the native NPM-
ALK led to sustained growth of the target cells
(Figure 1A). Although they displayed somewhat higher
transfection efﬁciency (Supplemental Figure S1), the cells
expressing inactive NPM-ALK had reached the growth
plateau by week 2 and began to decline shortly afterward,
similar to untransfected cells. The same pattern of cell
growth was seen in three independent consecutive experi-
ments, in which the transfection of CD4þ T cells with wild-
type NPM-ALK resulted in the establishment of cell lines
designated NA1, NA2, and NA3. These cell lines display a
steady growth rate (Figure 1B) and remain in continuous
culture for at least 8 months, whereas the control cell pop-
ulations ceased to grow by 3 to 4 weeks of culture
(Supplemental Figure S2). The NA1, NA2, and NA3 cell
lines display sustained expression of NPM-ALK, as well as
phosphorylation of the kinase, similar to the control ALKþ
ALCLederived SUDHL-1 cells (Figure 1C). These cell
lines also display phosphorylation of the direct target of
NPM-ALK, STAT3, and of its indirect, mTORC1-
dependent target S6RP. Cells of the NA1, NA2, and NA3
lines are also very large, matching the size of SUDHL-1
cells and markedly exceeding the size of the control
CD3- and CD28-stimulated CD4þ T cells (Figure 1F).
Furthermore, these cells can migrate (Figure 1D) and form
colonies (Figure 1E) and thus display additional features of
transformed cells.
Characteristics of the NPM-ALKeTransformed Cells
We next examined the morphology and immunophenotype
of the NPM-ALKetransformed CD4þ T cells. These cells
displayed predominantly large nuclei with prominent
nucleoli and a moderate to abundant amount of the eosin-
ophilic cytoplasm (Figure 2A). In addition to expressing
NPM-ALK, these cells weakly expressed T-cellerelated
CD3 antigen and strongly expressed proliferation-related
Ki-67 antigen, as determined by immunohistochemistry.
Of note, the cells universally and strongly expressed CD30
and IRF4 (alias MUM1) antigens. Marked loss of CD3
expression was conﬁrmed by ﬂow cytometry, and dimin-
ished expression of CD5 and strong expression of CD4 and
CD25 were also noted (Figure 2B). Strong CD30 expres-
sion was also conﬁrmed by this method (Figure 2D).
The cells further mimicked ALKþ ALCL cells by var-
iably expressing the T-cell markers CD2 and CD7
(Supplemental Table S1).
Because ALKþ ALCL cells universally express the
immunosuppressive molecules IL-1014 and PD-L1,15 we
next examined the NPM-ALKetransduced CD4þ cells for
expression of these two immunosuppressive molecules.
Indeed, both IL-10 and PD-L1 were expressed by the
transduced cells, similar to the ALKþ ALCLederived cell
lines (Figure 2, C and E).ajp.amjpathol.org - The American Journal of Pathology
Figure 1 NPM-ALKeinduced malignant transformation
of normal human CD4þ T lymphocytes. A: Cell growth
curves of NPM-ALKeexpressing CD4þ T cells. Puriﬁed CD4þ
T cellswere stimulatedwith bead-immobilized CD3 andCD28
antibodies and either transduced with wild-type NPM-ALK
(NA1)or enzymatically inactiveNPM-ALKmutant (KD) or left
untransfected. Triplicate cell cultures were counted using a
cell counter. B: Cell growth curves of NPM-ALKetransfected
CD4þ T cells (NA1, NA2, NA3) from three separate, consec-
utive experiments. C: Activation of ALK, STAT3, andmTORC1
pathways as determined by phosphorylation status of ALK,
STAT3, and S6RP. Expression of total NPM-ALK and b-actin
(ACTB) served as controls. ALKþ ALCLederived cell line
SUDHL-1, ALK-ALCL cell line 2B, and normal unstimulated
CD4þ T cells were used as additional positive and negative
controls. D: Migration of NPM-ALKetransfected cells
determined using a Transwell culture system. Cells trans-
fected with the enzymatically inactive NPM-ALK (KD) and
untransfected cells (Ctrl) served as controls. PZ 0.01 for
NA1 and PZ 0.04 for NA3 versus combined KD and Ctrl. E:
Colony formation by the NPM-ALKetransfected NA1, NA2,
NA3, and control ALKþ ALCLederived SUDHL-1 cells. F: Cell
volume of NPM-ALKetransfected and untransfected CD4þ T
cells as determined by cell counter analysis (Beckman
Coulter, Brea, CA). The ALKþ ALCLederived cell line SUDHL-
1 served as a positive control.
NPM-ALK Transforms Normal Human T CellsTo further characterize the NPM-ALKetransformed
CD4þ T cells, we evaluated their karyotype and clonality.
Both NA1 and NA2 cells displayed essentially normal cy-
togenetics, with only occasional random changes identiﬁed
(Supplemental Figure S3). However, these two cell lines, as
well as NA3, displayed from two to four distinct peaks in
the T-cell receptor gamma chain rearrangement PCR study
that used two separate primer pairs (Supplemental Table S2),
indicating the monoclonal to oligoclonal nature of the
transformed CD4þ T lymphocytes.The American Journal of Pathology - ajp.amjpathol.orgTransformed Cells are Strictly NPM-ALKeDependent
In the next series of experiments, we determined the effects of
NPM-ALK suppression on these cells, using ﬁrst a highly
selective ALK inhibitor16 and then ALK-targeting siRNA.
Cell signaling was ALK-dependent in the transformed cells,
as documented by the ALK inhibitoreinduced suppression
of phosphorylation of the key proteins (ie, ALK itself,
STAT3, and S6RP) (Figure 3A). A similar result was ob-
tained in the NPM-ALKetransfected epithelial HEK 2931975
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1976cells, although a higher dose of the inhibitor had to be used to
suppress ALK, STAT3, and S6RP phosphorylation, because
of the high concentration of NPM-ALK expressed by these
easily transfectable cells (Supplemental Figure S4). HEK 293
cells transfected with the inactive NPM-ALK-KD mutant
failed to phosphorylate ALK, STAT3, and S6RP, further
supporting the key role of NPM-ALK in their activation.
Because expression of CD30, the hallmark of ALKþ
ALCL, has been reported to be NPM-ALKedependent,17 we
examined whether this is the case in the NPM-ALKetrans-
formed CD4þ T cells. Indeed, ALK inhibition diminished
CD30 expression not only in the ALKþ ALCLederived cells
but also in the transformed CD4þ T cells, whereas it had no
effect on CD30 expression in cells from an ALK T-cell
lymphoma (Figure 3B). Similar to CD30, expression of the
immunosuppressive proteins PD-L1 and IL-10 was ALK-
dependent in the NPM-ALKetransformed CD4þ T cells
(Figure 3, C and D). ALKwas also critical for the transformed
CD4þ T cells on the functional level, because ALK inhibition
suppressed their growth (Figure 3E and Supplemental
Figure S5A). Depletion of NPM-ALK by siRNA yielded re-
sults similar to its inhibition, including loss of ALK, STAT3,
and S6RP phosphorylation (Figure 3F), loss of IL-10 and
PD-L1 expression (Figure 3, G and I), and impairment of cell
growth (Figure 3H and Supplemental Figure S5B).In Vivo Tumor Formation
The NPM-ALKetransformed cells are capable of forming
tumors in vivo as xenotransplants in the immunodeﬁcient
NSG mice (Figure 4). Within 5 weeks after intraperitoneal
injection of the transformed cells, three of the ﬁve mice
developed large tumors inﬁltrating the peritoneal wall,
compared with four of the ﬁve mice injected with ALKþ
ALCL cells (Figure 4A). These tumors were indistinguish-
able from native ALKþ ALCL, as determined by the
immunophenotype, including variable loss of T-cell anti-
gens, expression of NPM-ALK, CD30, and high prolifera-
tive rate and anaplastic large-cell morphology (Figure 4, B
and C, and Supplemental Table S3). Taken together, these
ﬁndings indicate that NPM-ALK induces malignant trans-
formation of normal human CD4þ T lymphocytes.Figure 2 Morphological and immunophenotypic features of NPM-
ALKetransformed CD4þ T cells. A: H&E staining and immunohistochemical
analysis for NPM-ALK, CD30, IRF4 (alias MUM1), CD3, and Ki-67 in NA1 cells.
B: Multiparameter ﬂow cytometry analysis of NA1 cells for expression of T-cell
markers CD2 and CD3, and CD4 and CD25. C: Expression of IL-10 mRNA
determined by RT-qPCR in NA1 and NA2 cells, with CD3 and CD28estimulated,
NPM-ALKeuntransfected CD4þ T cells (Ctrl) serving as negative control. ALKþ
ALCL cell lines SUDH-L1 and SUP-M2 served as positive controls. *PZ 0.01 for
the experimental versus control cells. D: Flow cytometry analysis of the NA1 and
NA2 for CD30 expression. ALKþ ALCLederived SUDHL-1 and mantle cell lym-
phomaederived Jeko cell lines served as positive and negative control, respec-
tively. E: Expression of the immunosuppressive PD-L1/CD274 protein by NA1,
NA2, and control SUDHL-1 cells. Original magniﬁcation: 200;400 (insets).
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Figure 3 NPM-ALKedependence of the transformed CD4þ T cells. AeD: Suppressive effect of the ALK inhibitor CEP-28122 (100 nmol/L) on phosphor-
ylation of the cell-signaling proteins ALK, STAT3, and S6RP in NA1, NA2, and control SUDHL-1 cells (A); expression of CD30, with CD30-ALK T-cell line 2A
serving as a negative control (B); expression of PD-L1 (C); and synthesis of IL-10 (D). E: Effects of ALK inactivation by CEP-28122 on cell growth (left panel),
cell proliferation (middle panel), and cell apoptotic rate (right panel). ALK T-cell lines MyLa2059 and MyLa3675 and ALKþ ALCL cell line SUDHL-1 served as
controls. FeI: Depletion of NPM-ALK mediated by ALK siRNA and its effect on phosphorylation of the cell-signaling proteins STAT3 and S6RP (F), IL-10
expression (G), cell growth (H), and PD-L1 expression (I). Nonspeciﬁc (NS) siRNA was used as a negative control (FeI). BrdU, bromodeoxyuridine.
NPM-ALK Transforms Normal Human T CellsDiscussion
Our understanding of carcinogenesis has been facilitated by
development of various experimental models, including
tumor-derived cell lines and oncogene-expressing transgenic
mice, but these models have signiﬁcant limitations. Only a
handful of cell lines exist for any given malignancy, and they
originate almost exclusively from aggressive, clinically
advanced tumors, which precludes study of the early stages
of carcinogenesis and the mechanisms of progression.
Essentially all transgenic mouse models recapitulate only
some features of the human malignancies; this certainly is the
case with NPM-ALK transgenic mice. Efforts of several
research groups using different gene promoters have resulted
in the development of NPM-ALKedriven lymphomas, but
all of these lymphomas were of either diverse B-cell or
immature T-cell origin.7,8 None of the transgenic mouse
models truly recapitulate features of ALKþ ALCL, aThe American Journal of Pathology - ajp.amjpathol.orgmalignancy of mature CD4þ T lymphocytes with highly
distinct morphology and phenotype.
In vitro malignant transformation of normal human cells
has long been a goal of cancer research. The efforts to
recreate carcinogenesis in this manner have met with some
success, most notably in immortalizing B lymphocytes
using an oncogenic virus and epithelial cells using a com-
bination of oncogenes. Although normal B lymphocytes can
routinely be immortalized by human herpesvirus 4 (HHV-4;
alias EpsteineBarr virus, or EBV),18 the transformed cells
most closely resemble lymphoproliferative disorders seen in
transplant patients and other immunodeﬁcient individuals,
rather than bona ﬁde lymphomas occurring in the population
at large. Furthermore, the EBV genome contains almost 100
genes, with expression of at least nine members from the
EBNA and PSMB (alias LMP) gene families being seem-
ingly critical to achieving immortalization. Weinberg and
colleagues19e21 succeeded in neoplastic transformation of1977
Figure 4 Growth of the transformed CD4þ T
cells in vivo. A: Ability of NPM-ALKetransfected
CD4þ T lymphocytes to form tumors in immuno-
deﬁcient mice. NA1 and control SUDHL-1 cells
were transfected with a vector containing the
luciferase gene, injected intraperitoneally at 3 
106 cells per mouse. The mice were examined for
the presence of bioluminescence 5 weeks later. B:
Flow cytometry detected expression of T-cell
markers CD5 and CD3, and CD4 and CD3, by iso-
lated tumor cells. C: Representative images of H&E
staining and immunohistochemical staining for
expression of NPM-ALK, CD30, CD2, CD3, and Ki-67
by the tumor tissues. Original magniﬁcation,
400.
Zhang et alnormal human ﬁbroblasts and primary breast epithelial cells
by simultaneously using three separate retroviral vectors
containing genes encoding the hTERT unit of telomerase,
the HRAS oncogene, and the simian virus 40 (SV40) early
response region coding for large and small viral T anti-
gens. Thus, three and perhaps four distinct genes were
required to accomplish the transformation. Perhaps more
importantly, these gene combinations, and speciﬁcally the
SV40 T antigen or antigens, have not been unequivocally
implicated in pathogenesis of the naturally occurring human
malignancies.
In this context, it is remarkable that we succeeded in
transforming normal human CD4þ T lymphocytes using a
single oncogene NPM-ALK, and that the transformed cells
were morphologically and immunophenotypically virtually
indistinguishable from the patient-derived ALKþ ALCL.
Previous studies have demonstrated that NPM-ALK tyro-
sine kinase is a very powerful oncogene, one that is capable
of activating several key cell-signaling pathways, including
STAT3 and mTORC1.1e3,11e13 Activation of these multiple
pathways modulates expression of many diverse genes that
regulate the key oncogenic cell functions, including sus-
tained cell growth and evasion of immune response. This
pluripotency of ALK, a cell-surface receptor in its native
form, is the most likely cause of its ability to transform the
normal CD4þ T cells. In principle, other cell-surface tyro-
sine kinase receptors (such as the EGF-R family or even the
IL-3R-mimicking cytoplasmic BCR-ABL (encoded by
BCR-ABL1), which is very powerfully oncogenic in its own
right and shares a number of characteristics with NPM-
ALK22), as well as the other oncogenic forms of ALK,
including ELM4-ALK,1e3 should also be able to effectively
transform in vitro the normal cells they target in vivo.1978It is interesting that the NPM-ALK immortalized cells are
clonal, given the high transduction rate of CD4þ T cells
(Supplemental Figure S1). A similar phenomenon has also
been noted in the multigene, SV40 T antigenebased cell
transformation system,21 and it is a norm in the transgenic
mousemodels, even though the transgene is expressed in entire
tissues, or even thewhole organism.At least two scenarios (not
mutually exclusive) may be considered for explaining this
general phenomenon. In the ﬁrst scenario, additional genetic
changes are always required to achieve malignant cell trans-
formation. In the present study, the high success rate of
immortalization achieved in several separate experiments, the
normal karyotype of the NPM-ALKetransformed clones, and
the young age of the ALKþ ALCL patients argue to some
degree against this possibility in our system. The ﬁnding that
highly malignant rhabdoid cancers in children display very
fewgenetic changes, with a loss of a SMARCB1 gene being the
sole common genomic lesion,23 also supports this conclusion.
However, the ability of NPM-ALK to impair DNA repair,
resulting in an increased mutation rate,24 suggests that sec-
ondary genetic changes can occur and may be required.
In the second scenario, only a small subset of the CD4þ T
lymphocytes undergoes the effective NPM-ALKeinduced
malignant transformation. CD4þ T cells are phenotypically
and functionally diverse, so it is possible that only a minor
subset becomes transformed by NPM-ALK. In accord, a
recent study indicates a resemblance of ALKþALCL cells to
the Th17 subset of the CD4þ T lymphocytes.25 Furthermore,
ALKþ ALCL may contain a very minor stem cell population
critical for their development, as postulated recently for
mucosa-associated lymphoid tissue (MALT) B-cell lym-
phoma.26 Our model should permit answering these funda-
mental questions with great precision, and the results mayajp.amjpathol.org - The American Journal of Pathology
NPM-ALK Transforms Normal Human T Cellswell be applicable to other models of carcinogenesis,
including mice transgenic for NPM-ALK (and likely also for
other tyrosine kinases and possibly for oncogenes in general).
Recently, Newrzela et al27 described an interesting model
in which highly puriﬁed murine mature T cells were trans-
duced with NPM-ALK or with another highly potent onco-
gene, DTrkA, and then were injected into Rag-1edeﬁcient
mice. Although mice inoculated with the oncogene-
transduced T cells obtained from immunocompetent mice
with a full T-cell receptor (TCR) repertoire typically failed to
establish tumors, mice injected with such T cells obtained
from immune-impaired mice transgenic for TCR developed
clonal T-cell tumors with high frequency. Of note, coin-
jection of T cells with the full TCR repertoire and not
transduced with the oncogene abrogated the ability of TCR
transgenic, oncogene-transduced T cells to establish tumors.
This ﬁnding clearly points to the key role of T-cellebased
immunosurveillance in inhibiting T-cell lymphomagenesis.
It is interesting in this context that we succeeded in trans-
forming T cells from healthy individuals. There are at least
two major differences between our experimental system and
that of Newrzela et al.27 In our system, we dealt with human
cells, and the outgrowth of the transformed cells occurred
in vitro. The former difference may not have been critical,
considering that tumors did develop in the recipient mice as
long as the TCR transgenic T cells were used for transduction
with the NPM-ALK or DTrkA oncogene. However, the
in vivo milieu, speciﬁcally the antigen-presenting cells, is
likely required to mount an effective inhibition of the
oncogene-expressing cells by normal immune T cells.
In summary, the oncogenic tyrosine kinase NPM-ALK is
capable of transforming normal CD4þ T cells in vitro and of
conferring on these cells morphological and immunophe-
notypic features characteristic of patient-derived ALKþ
ALCL cells and tissues. Here, we have documented effec-
tive malignant transformation of normal human cells by a
single potent oncogene, with the product cells faithfully
recapitulating malignant cells encountered in ALKþ ALCL
patients. Cells generated in this manner should prove
invaluable in studying the early stages of oncogenesis and,
probably, the mechanisms of progression. They should also
be useful in evaluating anticancer agents, including ALK
inhibitors, which have already shown substantial efﬁcacy in
ALK-driven malignancies.28,29Supplemental Data
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